ArticleVaccines2021
Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.NPJ vaccines · 2026Review
- Development of a Novel Polyleucine-Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- The Different Cellular Entry Routes for Drug Delivery Using Cell Penetrating Peptides.Biology of the cell · 2025Review
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Applications of cell penetrating peptide-based drug delivery system in immunotherapy.Frontiers in immunology · 2025Review
- Beyond Transduction: Anti-Inflammatory Effects of Cell Penetrating Peptides.Molecules (Basel, Switzerland) · 2024Review
- Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccinesFrontiers in immunology · 2024Article
- Lawsone Unleashed: A Comprehensive Review on Chemistry, Biosynthesis, and Therapeutic Potentials.Drug design, development and therapy · 2024Review
- Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens.Exploration of drug science · 2024Article
- Liposomal Formulations of a Polyleucine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer.Pharmaceutics · 2023Article
- The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines.Vaccines · 2023Article
- Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery.Pharmaceutics · 2023Review
- Development of Multilayer Nanoparticles for the Delivery of Peptide-Based Subunit Vaccine against Group APharmaceutics · 2022Article
- Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems.Pharmaceutics · 2022Article
- Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens.PloS one · 2022Article
- Cell penetrating peptide: A potent delivery system in vaccine development.Frontiers in pharmacology · 2022Review
- Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Peptide-based vaccine development represents a highly promising strategy for preventing Group A Streptococcus (GAS) infection. However, these vaccines need to be administered with the help of a delivery system and/or immune adjuvant. Cell-penetrating peptides (CPPs) have been used as a powerful tool for delivering various therapeutic agents, including peptides, as they can overcome the permeability barrier of cell membranes. Here, we used CPPs to deliver our lead lipopeptide-based vaccine (LCP-1). CPPs were anchored through a spacer to LCP-1-bearing multilamellar and unilamellar liposomes and administered to Swiss outbred mice. Tat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.